Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer.
GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in an advanced stage of clinical development. This article reviews the biological rationale underpinning the design of ongoing studies with the vaccine as well as its immunogenicity and clinical activity. It places GV1001 in the context of other immunotherapeutic approaches targeting telomerase and assesses the chances of the vaccine becoming a future standard of care in the treatment of cancer.
Shaw
V E
VE
Liverpool CR-UK Centre, NIHR Pancreas Biomedical Research Unit, Liverpool Experimental Cancer Medicine Centre, School of Cancer Studies, The Duncan Building, Daulby Street, Liverpool, L69 3GA, UK.
Naisbitt
D J
DJ
Costello
E
E
Greenhalf
W
W
Park
B K
BK
Neoptolemos
J P
JP
Middleton
G W
GW
D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D009369:Neoplasms / Q000628:therapy*; D010446:Peptide Fragments / Q000009:adverse effects / Q000276:immunology*; D019098:Telomerase / Q000009:adverse effects / Q000276:immunology*; D014611:Vaccination / Q000009:adverse effects / Q000379:methods*
D019496:Cancer Vaccines; D010446:Peptide Fragments; C514987:GV1001 peptide; D019098:Telomerase